Home > Publications database > Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. > print

001     170092
005     20240229133705.0
024 7 _ |a 10.1002/pbc.29267
|2 doi
024 7 _ |a pmid:34347371
|2 pmid
024 7 _ |a 0098-1532
|2 ISSN
024 7 _ |a 1096-911X
|2 ISSN
024 7 _ |a 1545-5009
|2 ISSN
024 7 _ |a 1545-5017
|2 ISSN
024 7 _ |a altmetric:111146528
|2 altmetric
037 _ _ |a DKFZ-2021-01755
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Steinbügl, Mona
|b 0
245 _ _ |a Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors.
260 _ _ |a New York, NY
|c 2021
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642412199_22337
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Dec;68(12):e29267
520 _ _ |a Refined therapy has helped to improve survival rates in rhabdoid tumors (RT). Prognosis for patients with chemoresistant, recurrent, or progressive RT remains dismal. Although decitabine, an epigenetically active agent, has mainly been evaluated in the management of hematologic malignancies in adults, safety in children has also been demonstrated repeatedly.A retrospective series of patients who received decitabine upon relapse or progression following therapy according to the EU-RHAB regimen is presented. Due to the retrospective nature of analyses, response was defined as measurable regression of at least one lesion on imaging. 850k methylation profiling was done whenever tumor tissue was available.A total of 22 patients with RT of any anatomical localization were included. Most patients (19/22) presented with metastases. All received low-dose decitabine with or preceding conventional chemotherapy. Patients received a median of two (1-6) courses of decitabine; 27.3% (6/22) demonstrated a radiological response. Molecular analyses revealed increased methylation levels in tumors from responders. No excessive toxicity was observed. Clinical benefits for responders included eligibility for early phase trials or local therapy. Responders showed prolonged time to progression and overall survival. Due to small sample size, statistical correction for survivorship bias demonstrated no significant effect on survival for responders.Patients with RT demonstrate promising signs of antitumor activity after multiagent relapse therapy including decitabine. Analyses of methylation data suggest a specific effect on an epigenetic level. We propose to consider decitabine and other epigenetic drugs as candidates for further clinical investigations in RT.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a ATRT
|2 Other
650 _ 7 |a decitabine
|2 Other
650 _ 7 |a malignant rhabdoid tumor
|2 Other
650 _ 7 |a relapsed and refractory rhabdoid tumors
|2 Other
700 1 _ |a Nemes, Karolina
|b 1
700 1 _ |a Johann, Pascal
|0 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8
|b 2
|u dkfz
700 1 _ |a Kröncke, Thomas
|b 3
700 1 _ |a Tüchert, Stefanie
|b 4
700 1 _ |a da Costa, Maria Joao Gil
|b 5
700 1 _ |a Ebinger, Martin
|0 0000-0002-4229-8058
|b 6
700 1 _ |a Schüller, Ulrich
|b 7
700 1 _ |a Sehested, Astrid
|b 8
700 1 _ |a Hauser, Peter
|0 0000-0002-8307-8975
|b 9
700 1 _ |a Reinhard, Harald
|b 10
700 1 _ |a Sumerauer, David
|b 11
700 1 _ |a Hettmer, Simone
|0 0000-0003-1709-4448
|b 12
700 1 _ |a Jakob, Marcus
|b 13
700 1 _ |a Hasselblatt, Martin
|b 14
700 1 _ |a Siebert, Reiner
|b 15
700 1 _ |a Witt, Olaf
|0 P:(DE-He78)143af26de9d57bf624771616318aaf7c
|b 16
|u dkfz
700 1 _ |a Gerss, Joachim
|b 17
700 1 _ |a Kerl, Kornelius
|0 0000-0002-5676-8102
|b 18
700 1 _ |a Frühwald, Michael C
|0 0000-0002-8237-1854
|b 19
773 _ _ |a 10.1002/pbc.29267
|0 PERI:(DE-600)2130978-4
|n 12
|p e29267
|t Pediatric blood & cancer
|v 68
|y 2021
|x 1545-5017
909 C O |p VDB
|o oai:inrepo02.dkfz.de:170092
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)143af26de9d57bf624771616318aaf7c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-02-02
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PEDIATR BLOOD CANCER : 2019
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-02
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-02-02
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21